Literature DB >> 28417246

Mammalian target of rapamycin (mTOR) as a potential therapeutic target in various diseases.

Avileen Kaur1, Saurabh Sharma2.   

Abstract

Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that belongs to Phosphatidylinositol-3-kinase related kinase superfamily. The signaling pathways of mTOR are integrated through the protein complexes of mTORC1 and mTORC2. mTORC1 controls protein synthesis, cell growth, proliferation, autophagy, cell metabolism, and stress responses, whereas mTORC2 seems to regulate cell survival and polarity. Dysregulation of the mTOR pathway has been implicated in the pathophysiology of a number of disease conditions, including cancer, cardiovascular, neurodegenerative, and various renal diseases. The hyperactivation of the mTOR pathway leads to increase in cell growth and proliferation and also has been documented to stimulate tumor growth. Therefore, investigation of the involvement of mTOR and its downstream pathways in various diseases intensively preoccupied scientific community. The present review is focussed on recent advances in the understanding of the mTOR signaling pathway and its role in health and various diseases.

Entities:  

Keywords:  Autophagy; Cell growth; Mammalian target of rapamycin (mTOR); Phosphatidylinositol-3-kinase (PI3K); Proliferation

Mesh:

Substances:

Year:  2017        PMID: 28417246     DOI: 10.1007/s10787-017-0336-1

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  149 in total

1.  FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions.

Authors:  R T Peterson; P A Beal; M J Comb; S L Schreiber
Journal:  J Biol Chem       Date:  2000-03-10       Impact factor: 5.157

2.  Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways.

Authors:  Jessica L Yecies; Hui H Zhang; Suchithra Menon; Sihao Liu; Derek Yecies; Alex I Lipovsky; Cem Gorgun; David J Kwiatkowski; Gökhan S Hotamisligil; Chih-Hao Lee; Brendan D Manning
Journal:  Cell Metab       Date:  2011-07-06       Impact factor: 27.287

Review 3.  Current development of mTOR inhibitors as anticancer agents.

Authors:  Sandrine Faivre; Guido Kroemer; Eric Raymond
Journal:  Nat Rev Drug Discov       Date:  2006-08       Impact factor: 84.694

4.  Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells.

Authors:  Boris Shor; Jiang Wu; Quazi Shakey; Lourdes Toral-Barza; Celine Shi; Max Follettie; Ker Yu
Journal:  J Biol Chem       Date:  2010-03-16       Impact factor: 5.157

5.  Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats.

Authors:  Núria Lloberas; Josep M Cruzado; Marcella Franquesa; Immaculada Herrero-Fresneda; Joan Torras; Gabriela Alperovich; Inés Rama; August Vidal; Josep M Grinyó
Journal:  J Am Soc Nephrol       Date:  2006-04-05       Impact factor: 10.121

6.  TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity.

Authors:  Mickael Decressac; Bengt Mattsson; Pia Weikop; Martin Lundblad; Johan Jakobsson; Anders Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-22       Impact factor: 11.205

7.  Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila.

Authors:  Yuzuru Imai; Stephan Gehrke; Hua-Qin Wang; Ryosuke Takahashi; Kazuko Hasegawa; Etsuro Oota; Bingwei Lu
Journal:  EMBO J       Date:  2008-08-14       Impact factor: 11.598

8.  Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure.

Authors:  Ping Zhang; Xin Xu; Xinli Hu; Elza D van Deel; Guangshuo Zhu; Yingjie Chen
Journal:  Circ Res       Date:  2007-03-15       Impact factor: 17.367

9.  An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.

Authors:  Carson C Thoreen; Seong A Kang; Jae Won Chang; Qingsong Liu; Jianming Zhang; Yi Gao; Laurie J Reichling; Taebo Sim; David M Sabatini; Nathanael S Gray
Journal:  J Biol Chem       Date:  2009-01-15       Impact factor: 5.157

10.  Pathological hypertrophy amelioration by PRAS40-mediated inhibition of mTORC1.

Authors:  Mirko Völkers; Haruhiro Toko; Shirin Doroudgar; Shabana Din; Pearl Quijada; Anya Y Joyo; Luis Ornelas; Eri Joyo; Donna J Thuerauf; Mathias H Konstandin; Natalie Gude; Christopher C Glembotski; Mark A Sussman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-10       Impact factor: 11.205

View more
  26 in total

1.  Low-concentration DMSO accelerates skin wound healing by Akt/mTOR-mediated cell proliferation and migration in diabetic mice.

Authors:  Wei Guo; Wei Qiu; Xiang Ao; Weiqiang Li; Xiao He; Luoquan Ao; Xueting Hu; Zhan Li; Ming Zhu; Donglin Luo; Wei Xing; Xiang Xu
Journal:  Br J Pharmacol       Date:  2020-04-07       Impact factor: 8.739

Review 2.  The role of Wnt/mTOR signaling in spinal cord injury.

Authors:  Peng Cheng; Hai-Yang Liao; Hai-Hong Zhang
Journal:  J Clin Orthop Trauma       Date:  2022-01-04

3.  Current progress in the therapeutic options for mitochondrial disorders.

Authors:  E Koňaříková; A Marković; Z Korandová; J Houštěk; T Mráček
Journal:  Physiol Res       Date:  2020-11-02       Impact factor: 1.881

4.  Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia.

Authors:  Zheng Ge; Chunhua Song; Yali Ding; Bi-Hua Tan; Dhimant Desai; Arati Sharma; Raghavendra Gowda; Feng Yue; Suming Huang; Vladimir Spiegelman; Jonathon L Payne; Mark E Reeves; Soumya Iyer; Pavan Kumar Dhanyamraju; Yuka Imamura; Daniel Bogush; Yevgeniya Bamme; Yiping Yang; Mario Soliman; Shriya Kane; Elanora Dovat; Joseph Schramm; Tommy Hu; Mary McGrath; Zissis C Chroneos; Kimberly J Payne; Chandrika Gowda; Sinisa Dovat
Journal:  Leukemia       Date:  2021-02-02       Impact factor: 11.528

Review 5.  Valproic Acid: A Potential Therapeutic for Spinal Cord Injury.

Authors:  Conghui Zhou; Songfeng Hu; Benson O A Botchway; Yong Zhang; Xuehong Liu
Journal:  Cell Mol Neurobiol       Date:  2020-07-28       Impact factor: 5.046

Review 6.  Cell Death and Exosomes Regulation After Myocardial Infarction and Ischemia-Reperfusion.

Authors:  Xun Wu; Chukwuemeka Daniel Iroegbu; Jun Peng; Jianjun Guo; Jinfu Yang; Chengming Fan
Journal:  Front Cell Dev Biol       Date:  2021-06-09

Review 7.  Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration.

Authors:  Henry Querfurth; Han-Kyu Lee
Journal:  Mol Neurodegener       Date:  2021-07-02       Impact factor: 14.195

8.  Genomic and Transcriptome Analysis to Identify the Role of the mTOR Pathway in Kidney Renal Clear Cell Carcinoma and Its Potential Therapeutic Significance.

Authors:  Xiangyu Che; Xiaochen Qi; Yingkun Xu; Qifei Wang; Guangzhen Wu
Journal:  Oxid Med Cell Longev       Date:  2021-06-07       Impact factor: 6.543

9.  Rapamycin Synergizes with Cisplatin in Antiendometrial Cancer Activation by Improving IL-27-Stimulated Cytotoxicity of NK Cells.

Authors:  Wen-Jie Zhou; Kai-Kai Chang; Ke Wu; Hui-Li Yang; Jie Mei; Feng Xie; Da-Jin Li; Ming-Qing Li
Journal:  Neoplasia       Date:  2017-12-01       Impact factor: 5.715

10.  Low-dose rapamycin extends lifespan in a mouse model of mtDNA depletion syndrome.

Authors:  Stephanie E Siegmund; Hua Yang; Rohit Sharma; Martin Javors; Owen Skinner; Vamsi Mootha; Michio Hirano; Eric A Schon
Journal:  Hum Mol Genet       Date:  2017-12-01       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.